Outlook Therapeutics
OTLK
$8.74
Share price
-2.07%
Change (1 day)
646.58%
Change (1 year)
Categories
Outlook Therapeutics (OTLK) - P/B ratio
P/B ratio as of May 2024 : -8.54
According to Outlook Therapeutics
's latest financial reports the company has a price-to-book ratio of -8.54.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Outlook Therapeutics - P/B ratio (from 2016 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -4.21 | -127.18% |
| 2022-12-31 | 15.5 | 148.1% |
| 2021-12-31 | 6.25 | -139.58% |
| 2020-12-31 | -15.8 | 1668.62% |
| 2019-12-31 | -0.8925 | -54.97% |
| 2018-12-31 | -1.98 | -52.84% |
| 2017-12-31 | -4.20 | 29.27% |
| 2016-12-31 | -3.25 | |
| 2015-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | 1.97 | -123.09% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | 4.74 | -155.48% | 🇬🇧 UK |
 Novavax NVAX | -0.8453 | -90.10% | 🇺🇸 USA |
 Novocure
NVCR | 3.63 | -142.56% | Jersey |